Xenotropic murine leukemia virus (MLV)-related retrovirus (XMRV) was reported to be associated with prostate cancer by Urisman, et al. in 2006 and chronic fatigue syndrome (CFS) by Lombardi, et al. in 2009. To investigate this association, we independently evaluated plasma samples from 4 patients with CFS reported by Lombardi, et al. to have XMRV infection and from 5 healthy controls reported to be XMRV uninfected. We also analyzed viral sequences obtained from supernatants of cell cultures found to contain XMRV after coculture with 9 clinical samples from 8 patients. A qPCR assay capable of distinguishing XMRV from endogenous MLVs showed that the viral sequences detected in the CFS patient plasma behaved like endogenous MLVs and not XMRV. Single-genome sequences (N = 89) from CFS patient plasma were indistinguishable from endogenous MLVs found in the mouse genome that are distinct from XMRV. By contrast, XMRV sequences were detected by qPCR in 2 of the 5 plasma samples from healthy controls (sequencing of the qPCR product confirmed XMRV not MLV). Single-genome sequences (N = 234) from the 9 culture supernatants reportedly positive for XMRV were indistinguishable from XMRV sequences obtained from 22Rv1 and XMRV-contaminated 293T cell-lines. These results indicate that MLV DNA detected in the plasma samples from CFS patients evaluated in this study was from contaminating mouse genomic DNA and that XMRV detected in plasma samples from healthy controls and in cultures of patient samples was due to cross-contamination with XMRV (virus or nucleic acid).
Citation: Kearney MF, Spindler J, Wiegand A, Shao W, Anderson EM, Maldarelli F, et al. (2012) Multiple Sources of Contamination in Samples from Patients Reported to Have XMRV Infection. PLoS ONE 7(2): e30889. doi:10.1371/journal.pone.0030889
Editor: Cristian Apetrei, University of Pittsburgh Center for Vaccine Research, United States of America
Received: October 11, 2011; Accepted: December 22, 2011; Published: February 20, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: Dr. Coffin was a Research Professor of the American Cancer Society, with support from the FM Kirby Foundation. Funding for this research was provided by the Intramural Research Program of the National Cancer Institute. Dr. Mellors was supported by a contract from the National Cancer Institute (SAIC contract 25XS119). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Dr. Mellors is a consultant for Gilead Sciences, Merck, and RFS Pharma and owns share options in RFS Pharma. Dr. Shao is an employee of SIAC, Frederick. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.
In 2006, a novel infectious agent, xenotropic MLV-related virus (XMRV), was identified by hybridization to an oligonucleotide chip (“virochip”) and reported to be associated with prostate cancer . Subsequently, XMRV infection was reported to be associated with chronic fatigue syndrome (CFS) by Lombardi, et al. who detected XMRV, using PCR, in 67% of samples from CFS patients compared to 3.7% of samples from healthy controls . Such high frequencies of XMRV infection prompted concerns about widespread XMRV infection and stimulated research to determine the prevalence of XMRV infection worldwide. These efforts failed to detect XMRV in patients with either prostate cancer or CFS, even among a subset of patients from the original Lombardi, et al. study ,  – ,  , . These findings suggested that XMRV detection was the result of laboratory contamination , , , , , , which is possible whenever sensitive amplification methods are employed, such as PCR or viral replication in cell culture. False positive detection of XMRV in patient samples could arise from PCR amplification of contaminating XMRV nucleic acids or from amplification of closely related endogenous retroviruses in the mouse genome that are misidentified as XMRV. With regard to the latter possibility, several recent studies have shown frequent contamination of reagents and samples with mouse DNA , , . In addition, strong evidence that XMRV detection was the result of laboratory contamination came from a recent report that XMRV originated as a recombinant virus between two endogenous MLV proviruses (PreXMRV-1 and PreXMRV-2) between 1993 and 1996 during passage of a human prostate cancer xenograft in nude mice . Cells from the passaged xenograft gave rise to the 22Rv1 cell line, which produces large amounts of infectious XMRV and has been distributed to laboratories worldwide . The recombination event that gave rise to XMRV required multiple crossovers, and it is extremely unlikely that this complex event could have occurred more than once. Consequently, any virus whose sequence is closely related to this exact recombinant virus (XMRV) must have arisen from laboratory contamination by XMRV or its descendants. Indeed, since the generation and distribution of the 22Rv1 cell line, sublines of several other human cell lines, including Jurkat, 293T, and LNCap, have been reported to be contaminated with XMRV or similar viruses in laboratories using the 22Rv1 cell line . Other cell lines, also derived from cancers passaged in nude mice, have been shown to be infected with viruses derived from a variety of endogenous MLVs; however, these viruses are distinct from XMRV , , .
To investigate further the possibility that XMRV or MLV detection in patient samples was the result of laboratory contamination by XMRV or mouse DNA, we performed qPCR and single-genome sequencing analysis on plasma samples from CFS patients who were reportedly infected with XMRV  and from healthy, XMRV uninfected controls. We also performed single-genome sequencing on supernatants from cultures containing XMRV reportedly isolated from patient samples. Our analyses reveal strong evidence for three different types of laboratory contamination giving rise to false positive detection of XMRV in human samples: mouse genomic DNA contamination of plasma samples from CFS patients; XMRV nucleic acid contamination of plasma samples from healthy controls; and contamination with infectious XMRV in virus isolation cultures. These results indicate that detection of XMRV infection in the original study by Lombardi, et al. likely arose from laboratory contamination and cast serious doubt on claims of human infection by XMRV and other MLVs.
Patient Plasma Samples
Plasma samples from 4 patients with chronic fatigue syndrome (CFS) reported to be XMRV-infected by PCR and virus isolation, performed at the Whittemore-Peterson Institute (WPI) and the Leukocyte Biology Section (LBS), NCI-Frederick, respectively, and from 5 XMRV-uninfected, healthy controls were obtained from F. Ruscetti, NCI-Frederick with permission from J. Mikovits, WPI (Table 1). All donors signed informed consent forms and the study was approved by the Institutional Review Board at the WPI (Approval ID# IRB00000215). Blood samples were drawn into EDTA-containing tubes by Phlebotomy Services International at the donors homes on January 21, 2010 and shipped overnight to LBS. The blood was centrifuged in a BL2* laboratory used for tissue culture in the LBS, the plasma was removed, aliquoted, and frozen at −80. The specimens were not reopened prior to testing in the HIV Drug Resistance Program (DRP). Samples were blinded with respect to their putative XMRV status by WPI and LBS and were provided to the DRP in June 2010 for testing by our XMRV single copy assay (X-SCA) and our XMRV single-genome sequencing assay (X-SGS) described below. We assigned the 9 blinded plasma samples identification codes X1–X9. After completion of testing, samples were unblinded to compare our results with those obtained by WPI and reported by Lombardi, et al. (Table 1).
Supernatants of Virus Cultures Positive for XMRV Isolation from Patient Samples
LNCaP cells were co-cultured by LBS with plasma, PBMCs or tissues (collected from bone marrow biopsies) from 9 clinical specimens collected from 8 patients with putative XMRV infection. Virus-positive supernatants were subsequently used to infect human foreskin fibroblasts (HFFs). The same samples were opened multiple times for subculture experiments. Experimental cultures were kept in separate incubators from positive control cultures but were used in the same biological safety cabinets at different times. Samples of the HFF supernatants were provided to the DRP in February 2011 and we assigned them identifying codes DRP ID 1–9 (Table 2). To evaluate viral sequences in these culture supernatants we extracted viral RNA, synthesized cDNA, diluted cDNAs ~1011 -fold and performed X-SGS for gag and env as described below. The description of the patients' clinical symptoms, sample type used for virus isolation, and cell passaging details are shown in Table 2. An additional plasma sample was collected on March 11, 2010 from one of the 8 patients who had virus isolation performed. This plasma sample was among the 9 plasma samples described above that were tested by X-SCA (plasma identifier X5; culture supernatant identifier DRP PID 5). Single-genome sequences obtained from this plasma sample (X5) and the virus culture supernatant (DRP PID 5) were compared.
DNA and supernatants from 22Rv1 cells and the mammary carcinoma TA3.Cyc-T1 cell line derived from strain A mice, obtained from V. KewalRamani, NCI, were analyzed by X-SCA and X-SGS. Results from these cell lines were used as controls for sequences obtained from patient plasma samples. A subline of 293T cells was obtained from the LBS for use as an uninfected control, but was determined by Western blot to be infected with MLV or XMRV, was confirmed to be XMRV by sequence analysis, and is referred to as 293T-XMRV. Culture supernatant and DNA from these cells were subjected to X-SGS for comparison to virus reported to be isolated from patient plasma and tissues. We handled all cell culture supernatants in an area designated for cell culture and not in clean areas designated for processing of patient samples.
Nucleic Assay Detection with X-SCA
The X-SCA assay  is similar to the HIV single-copy assay (SCA) , and can be used to quantify XMRV nucleic acid in blood and blood products. In brief, virus from patient plasma is collected by centrifugation after addition of the Rous sarcoma virus vector RCAS, an internal virion control for recovery . cDNA was prepared from RNA in the pellet using random DNA hexamers as primers and subjected to PCR amplification using primers that are well conserved among XMRV and endogenous MLVs. Consequently, efficient amplification is achieved from both templates, and the assay can be used to detect either XMRV or MLV sequences in patient samples. The Taqman probe used for detection of amplified products was designed to span the signature 9–24 nt deletion in the XMRV gag leader absent from all endogenous MLV sequences (with the exception of PreXMRV-2) . This probe design results in a lower plateau level of fluorescence from sequences amplified from MLV than from XMRV (Figure 1a), likely due to inefficient binding and degradation of the probe during amplification of MLV templates (Figure 1a). The different fluorescence profiles produced by XMRV and MLV sequences permits their identification and differentiation .
Florescence intensity as a function of cycle number is shown for X-SCA amplifications initiated with dilutions of XMRV RNA and (a) endogenous MLVs found in mouse (TA3.Cyc-T1) genomic DNA or (b) patient plasma samples obtained from WPI and LBS. Red lines: XMRV standards; pink: CFS patient plasma samples; green: Normal control plasma. (c) Aligned sequences of the cloned amplicons detected in (b) from the indicated samples. The XMRV reference sequence matched vp62, virus from 22Rv1 cells, and Pre-XMRV-2.
XMRV single-genome sequencing (X-SGS)
The HIV single-genome sequencing assay (SGS)  was modified for amplification and sequencing of single sequences derived from XMRV and MLV templates (X-SGS). RNA from virions pelleted from cell culture supernatant was used to synthesize cDNA using an oligo-dT primer with reaction conditions described in Supporting Information (Appendix S1). The cDNA was diluted to <1 copy per well and amplified using primers targeting XMRV and MLV sequences listed in Supporting Information (Appendix S2). cDNA synthesis and PCR reaction components and conditions were as reported previously . Primers used to sequence single-genome amplicons are listed in Supporting Information (Appendix S2). The X-SGS gag protocol generates a 1.4 kb gag sequence and the X-SGS env protocol generates a 2.1 kb env sequence, which includes several of the distinctive recombination junctions described by Paprotka et al. in their paper on the origin of XMRV that demonstrated that XMRV is a laboratory artifact that arose by recombination between two MLVs called PreXMRV-1 and PreXMRV-2 . The total product of each SGS PCR positive reaction was sequenced. Contigs were generated and sequences aligned using ClustalW (http://www.genome.jp/tools/clustalw) and MEGA5 (http://www.megasoftware.net). Alignment trees were constructed using a neighbor-Joining method in MEGA5.
Detection of mouse mitochondrial DNA and mouse genomic DNA
We applied two previously developed assays to detect mouse DNA. The first was adapted from methods developed by W. Switzer, Centers for Disease Control and Prevention, Atlanta, GA, to measure the level of mouse mitochondrial DNA by detecting the cytochrome C oxidase subunit 2 (COX2) gene  (Appendix S3), and the second was adapted from O. Cingöz, Tufts University, Boston, MA, to detect intracisternal A particle (IAP) sequences . Genomic DNA extracted from as few as 0.0034 cells from the mouse cell line, TA3.Cyc1, could be detected using the IAP primer set shown in Supporting Information (Appendix S4). Primer sequences and reaction conditions are described in Supporting Information (Appendix S3, S4).
MLV-related sequences in plasma samples
X-SCA was performed on 9 plasma samples collected from donors, 5 of whom were reported in the 2009 Lombardi, et al. study . Four of the 9 were CFS patients previously reported to be XMRV positive and 5 were healthy controls reported to XMRV negative  (Table 1). The samples were coded to blind the analysis with regard to the putative XMRV status of the donor. X-SCA detected high levels of MLV, but no XMRV, in all 4 samples from CFS patients (Figure 1). For reference, Figure 1a shows the differential fluorescence seen with the amplification of endogenous MLV (DNA extracted from mouse cells) and XMRV RNA standards. Figure 1b shows the fluorescence profiles of the sequences amplified from the CFS patient plasma samples compared to an XMRV RNA standard curve. These data show that the amplification profiles from the CFS patient samples mimic those of MLV and not XMRV. Cloning and sequencing of the X-SCA products confirmed that the amplicons did not contain the gag deletion specific to XMRV and preXMRV-2 sequences (Figure 1c). We also tested the samples for XMRV or MLV DNA by performing X-SCA without the reverse transcriptase (RT) enzyme and found that the CFS patient samples contained MLV DNA that was amplifiable (data not shown). These results show that the retroviral sequences detected in the CFS plasma samples were more similar to endogenous MLV DNA than XMRV RNA, suggesting high levels of contamination with mouse genomic DNA. X-SCA did not detect MLV sequences in the samples from the healthy control patients but did detect XMRV nucleic acid in two of the 5 samples (X4 and X7) reported to be healthy controls by WPI. The X-SCA product was sequenced and determined to be an exact match to XMRV (Figure 1c). Repeat X-SCA testing of both samples gave the same results, implying that the contamination occurred during preparation of the samples and not during performance of the X-SCA assay. We do not know the source of XMRV sequences in the two healthy control samples. Both samples gave a positive PCR signal in reactions lacking RT, but neither sample was positive for XMRV or MLV sequences by X-SGS using an oligodT primer (Table 1). The latter result suggests that the samples may have contained XMRV DNA but not viral RNA molecules. These findings, taken together with the fact that XMRV originated by recombination between two endogenous MLVs in a xenograft of prostate cancer passaged in nude mice, makes it likely that sample contamination with XMRV was from cloned or PCR-amplified XMRV DNA. Additional sample was not available to differentiate further between these two types of DNA contamination.
Detection of mouse DNA sequences in patient plasma samples
Because the X-SCA results suggested high levels of mouse DNA contamination in the CFS patient samples, we used three experimental approaches to detect mouse DNA. We tested for mouse mitochondrial DNA using an assay that detects the COX2 gene (Table 1), for mouse genomic DNA using an assay that detects intracisternal A-particle (IAP) sequences  (Table 1), and we performed X-SGS of a 1.4 kb fragment of the XMRV/MLV gag gene to determine the source of the amplified nucleic acid in plasma samples (Table 1, Figure 2). The three methods yielded concordant results for all 9 samples and provided unequivocal evidence that the plasma samples provided to us from 4 of the CFS patients originally reported  to be XMRV infected were contaminated with mouse DNA (Table 1). No mouse mitochondrial or genomic DNA was detected in the 5 samples from healthy controls by the COX2, IAP, or X-SGS assay.
Phylogenetic structure of gag single-genome sequences obtained from CFS patients X2 (aqua) X3 (blue) X5 (green), and X8 (red), and TA3.Cyc-T1 mouse cells (black triangles). Also includes sequences of endogenous MLVs extracted from the C57Bl6 genome sequence , as well as XMRV isolates are included for comparison. Where there are multiple identical sequences in the mouse genome, only one is shown, with the number of identical sequences in parentheses.
To further analyze the MLV sequences obtained by X-SGS, we prepared neighbor-joining trees from the single-genome gag sequences obtained from the 4 CSF patient plasma samples and from sequences obtained from strain A mouse genomic DNA (extracted from TA3.Cyc-T1 cells). We compared these sequences to known endogenous MLV sequences  (Figure 2). Plasma samples from each of the 4 CFS patients contained MLV sequences indistinguishable from those found in mouse genomic DNA. Moreover, X-SGS did not detect XMRV sequences in any of the CFS patient samples, although, as expected for mouse DNA and described by Paprotka, et al , two of the sequences were an almost perfect match to preXMRV-2 in this region (one from X2 and one from X5). X-SGS was also performed on the env gene from patient X8 and compared to single-genome env sequences obtained from mouse cells (Figure 3). The majority of sequences in patient X8 contained large deletions, as seen in the highlighter plot of the alignment of Figure 3b (http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html). Similarly large env deletions were also present in the endogenous MLVs amplified by X-SGS from mouse genomic DNA, again confirming that mouse genomic DNA was the source of MLV sequences in the plasma samples from the CFS patients (Figure 3b).
(a) Neighbor-joining analysis of full-length env sequences from patient X8, the full length TA3 sequences, and endogenous MLV as shown in Figure 2. (b) Highlighter plot of single-genome sequence alignment of env sequences from patient X8 and from TA3.CycT1 mouse cells.
XMRV sequences of viruses obtained from co-cultures with patient samples
Although contaminating mouse genomic DNA can explain false positive results in PCR assays, it does not explain the isolation of replicating XMRV from patients reportedly infected with XMRV , , . We therefore performed X-SGS analysis of supernatants from human foreskin fibroblasts (HFF) or LNCaP cells infected with virus reportedly isolated from plasma, PBMCs or tissue from 8 patients with putative XMRV infection (Table 2). One of these patients (Patient 5; Table 2) was among the 9 patients from whom we had evaluated viral sequences in plasma samples (patient X5 in Table 1). As described above, plasma from patient X5 was positive for MLV sequences but not XMRV sequences by X-SCA, and was contaminated with mouse DNA.
X-SGS of env was performed on all 9 culture supernatants and on gag from a subset of three supernatants (PID 1, 2, 3). XMRV, but not MLV, sequences were detected in all 9 culture supernatants. As shown in Figures 4 and 5 and Table 3, all of the XMRV sequences detected in the supernatants were nearly indistinguishable from XMRV sequences found in well-characterized XMRV-infected cell lines. Specifically, Figure 4 shows the neighbor-joining tree and highlighter plot of XMRV env sequences found in the 9 culture supernatants compared to sequences obtained by X-SGS from 22Rv1 cells and from the 293T-XMRV subline. Phylogenetic analysis (Figure 4, 5) and calculations of genetic distance (Table 3) show that the viral sequences obtained from the co-culture supernatants from 8 different patients were nearly identical, and that these sequences are essentially the same as those from both 22Rv1 cells and 293T-XMRV cells. XMRV produced by 22Rv1 cells shows very low diversity (Figure 4, 5, Table 3), whereas the XMRV sequences from 293T-XMRV cells and co-culture supernatants were 2-16-fold more diverse (Table 3), consistent with acquisition of a few mutations during rounds of virus replication in cell culture that occurred during the co-culture procedure that included 2–10 passages. Moreover, the consensus sequences from the culture supernatants and the 293T-XMRV cells were identical to the consensus sequence of XMRV from 22Rv1 cells (with the exception of single nucleotide changes in PID 6 and 9). Because these analyses include a region in env (shaded in Fig. 4b) that contains multiple crossovers between PreXMRV-1 and -2 (events that occurred in the generation of XMRV and that are highly unlikely to occur twice as explained by Paprotka, et al. ), they provide very strong evidence that all of the viruses detected here arose from 22Rv1 cells.
(a) Neighbor-joining tree of single-genome env sequences from XMRV infected 293T cell supernatants, 22Rv1 cell supernatants, and supernatants from virus rescue experiments on samples 1–9. (b) Highlighter plots of the same sequences. PreXMRV-1 and -2 and the predicted recombinant (used as outgroup)  are included for comparison. The region of multiple crossovers inferred to have occurred between the two parental viruses is shaded.
(a) Neighbor-joining tree of single-genome gag sequences from XMRV infected 293T cell supernatants, 22Rv1 cell supernatants, and supernatants from virus rescue experiments on patients 1–3, and 5. (b) Highlighter plots of the same sequences as compared to XMRV VP62. PreXMRV-1 and -2 and the predicted recombinant (used as outgroup)  are included for comparison.
X-SGS of gag was also performed using supernatants of cultures treated with samples obtained from PIDs 1–3 and 5. Although these sequences were very similar, more detailed analyses revealed that the culture supernatants from PIDs 1, 3, and 5 had gag sequences that were most closely related to XMRV from 22Rv1 cells, whereas the culture supernatant from PID 2 had sequences identical to those from 293T-XMRV cells (Figure 5).
PID 5 was the only patient for whom both plasma and virus culture supernatant were tested. We found sequences in the plasma sample that were derived from mouse genomic DNA, and were very different sequences detected in the co-culture supernatant, which were indistinguishable from the XMRV produced by 22Rv1 cells. These findings indicate that the plasma sample and the virus co-culture from this patient were contaminated from at least two independent sources, each of which led to different false positive results for XMRV infection.
Our analyses of plasma samples independently collected from CFS patients previously reported to be XMRV-infected ,  and from healthy controls reported to be XMRV-uninfected , and of virus isolation co-culture supernatants identified three different types of sample contamination, leading to false positive detection of XMRV. First, we detected high levels of mouse genomic (both IAP and MLVs) and mouse mitochondrial DNA, but no XMRV sequences, in plasma samples from CFS patients, leading us to conclude that contaminating mouse genomic DNA in this set of plasma samples led to false positive PCR results for XMRV. Second, although the 5 plasma samples from healthy controls were free of mouse DNA, two of them contained contaminating XMRV nucleic acid – most likely plasmid or a PCR amplified DNA product – as shown by the PCR amplification profiles and confirmed by sequencing of the amplified product. Third, our analyses of sequences from viruses reportedly isolated from 8 patients with putative XMRV infection  revealed that the sequences did not differ among the patients and were indistinguishable from sequences of XMRV in XMRV-infected cell lines indicating that the cultures were cross-contaminated from infected cell lines used in the same laboratory. Specifically, the viruses reportedly isolated from patient samples exhibited very little diversity and were closely related to the 22Rv1 virus, consistent with a virus highly similar or identical to that found in the 22Rv1 cell line after a few cycles of virus replication in culture. These findings indicate that the putative isolations of replicating XMRV from patient samples were likely false positives as a result of cross-contamination of the cultures with XMRV from infected cell lines.
PCR and tissue culture are sensitive methods, and are, as a consequence, susceptible to contamination. Care must be taken both to prevent such contamination and to ensure that the analysis includes proper controls to exclude false positive results. The experimental samples and controls must be collected at the same time, using the identical materials, and processed together under identical conditions. Furthermore, it is important to develop strict criteria for declaring a sample positive, including a requirement that multiple methods should yield positive and negative results for the same samples, and the results should be reproducible. Our independent analyses of samples from patients reported to be XMRV-infected (12), refutes prior evidence of XMRV infection in these patients and argues against XMRV infection of human populations.
Our data show that there are at least three different ways contamination can be misinterpreted as XMRV or MLV infection of humans. The first is mouse DNA, which is a ubiquitous environmental contaminant that can find its way into experimental samples in many different ways. Examples include monoclonal antibodies or other bioproducts prepared in mice or mouse cells, chemicals, disposables, or other materials stored where mice can have access , , , , , , or handling of mouse specimens or cell lines in the same laboratory where human samples are being processed . Inbred strains of mice contain around 60 MLV proviruses per haploid genome that can be detected by PCR with an env-specific probe , and some wild subspecies contain even more. Given that approximately 50% of the proviruses may be deleted in the env region (Fig. 3), one cell may contain over 200 proviruses that can be detected by PCR with gag, pro, or pol primers, increasing the potential that trace amounts of mouse DNA can give rise to a positive PCR signal. The second source of contamination is cloned or amplified XMRV DNA, including DNA being used as a positive control in diagnostic tests. A microgram of XMRV DNA is approximately 1013 copies. Any laboratory that works with either cloned or amplified XMRV DNA is a potential source of contamination. The third source of contamination is inadvertent spread of XMRV originating from 22Rv1 cells to indicator cells co-cultivated with clinical samples. Although this virus is quite sensitive to human restriction factors such as tetherin and APOBECs 3F and 3G, many established cell lines, like 293T, do not express these factors, and cross-contamination can occur even in laboratories with considerable virology experience, leading to subsequent spread to other cell lines, as was observed for the 293T-XMRV cells reported here. Inadvertent contamination of other human cell lines provides a plausible explanation for XMRV contamination even in laboratories that have never cultured the 22Rv1 cell line.
Protocol for synthesizing long cDNA fragments.
Primer sequences for XMRV PCR amplification and for sequencing.
Protocol for mouse COX2 Quantitative PCR.
IAP detection protocol and primer sequences.
We thank V. KewalRamani and K. Lee, NCI, for providing tissue culture cells and supernatants used for control experiments and O. Cingöz (Tufts University, Boston MA) and W. Switzer (CDC) for providing technical advice. We also thank R. Wiltrout, J. Strathern, and V. Boltz, NCI, for helpful discussions and C. Kinna, S. Jordan, and S. Toms for administrative support.
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Conceived and designed the experiments: MK JMC. Performed the experiments: MK AW JS FR. Analyzed the data: MK JS AW JMC WS EA. Contributed reagents/materials/analysis tools: FM SL FR. Wrote the paper: MK JMC JWM SH.
- 1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, et al. (2006) Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS pathogens 2: e25.
- 2. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, et al. (2009) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326: 585–589.
- 3. Robinson MJ, Erlwein OW, Kaye S, Weber J, Cingoz O, et al. (2010) Mouse DNA contamination in human tissue tested for XMRV. Retrovirology 7: 108.
- 4. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, et al. (2010) Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 7: 10.
- 5. Satterfield BC, Garcia RA, Jia H, Tang S, Zheng H, et al. (2011) Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology 8: 12.
- 6. Hohn O, Strohschein K, Brandt AU, Seeher S, Klein S, et al. (2010) No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PloS one 5: e15632.
- 7. Cornelissen M, Zorgdrager F, Blom P, Jurriaans S, Repping S, et al. (2010) Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PloS one 5: e12040.
- 8. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, et al. (2010) Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PloS one 5: e8519.
- 9. Gray ER, Garson JA, Breuer J, Edwards S, Kellam P, et al. (2011) No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort. PloS one 6: e18096.
- 10. Shin CH, Bateman L, Schlaberg R, Bunker AM, Leonard CJ, et al. (2011) Absence of XMRV and other MLV-related viruses in patients with Chronic Fatigue Syndrome. Journal of virology.
- 11. Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, et al. (2011) No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected. Science.
- 12. Stang A, Petrasch-Parwez E, Brandt S, Dermietzel R, Meyer HE, et al. (2009) Unintended spread of a biosafety level 2 recombinant retrovirus. Retrovirology 6: 86.
- 13. Smith RA (2010) Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 7: 112.
- 14. Oakes B, Tai AK, Cingoz O, Henefield MH, Levine S, et al. (2010) Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology 7: 109.
- 15. Hue S, Gray ER, Gall A, Katzourakis A, Tan CP, et al. (2010) Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 7: 111.
- 16. Garson JA, Kellam P, Towers GJ (2011) Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection. Retrovirology 8: 13.
- 17. Sato E, Furuta RA, Miyazawa T (2010) An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV. Retrovirology 7: 110.
- 18. Paprotka T, Delviks-Frankenberry KA, Cingoz O, Martinez A, Kung HJ, et al. (2011) Recombinant Origin of the Retrovirus XMRV. Science.
- 19. Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, et al. (2009) Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. Journal of virology 83: 7353–7356.
- 20. Zhang YA, Maitra A, Hsieh JT, Rudin CM, Peacock C, et al. (2011) Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer biology & therapy 12:
- 21. Sfanos KS, Aloia AL, Hicks JL, Esopi DM, Steranka JP, et al. (2011) Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines. PloS one 6: e20874.
- 22. Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, et al. (2011) Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples. Advances in Virology 2011:
- 23. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. Journal of clinical microbiology 41: 4531–4536.
- 24. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. Journal of clinical microbiology 43: 406–413.
- 25. Switzer WM, Jia H, Zheng H, Tang S, Heneine W (2011) No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PloS one 6: e19065.
- 26. Jern P, Stoye JP, Coffin JM (2007) Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses. PLoS genetics 3: 2014–2022.
- 27. Jern P, Russell RA, Pathak VK, Coffin JM (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS pathogens 5: e1000367.
- 28. Mikovits JA, Huang Y, Pfost MA, Lombardi VC, Bertolette DC, et al. (2010) Distribution of xenotropic murine leukemia virus-related virus (XMRV) infection in chronic fatigue syndrome and prostate cancer. AIDS reviews 12: 149–152.
- 29. Mikovits JA, Lombardi VC, Pfost MA, Hagen KS, Ruscetti FW (2010) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Virulence 1: 386–390.
- 30. Huber BT, Oakes B, Tai AK, Cingoz O, Henefield MH, et al. (2010) Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology 7:
- 31. Tuke PW, Tettmar KI, Tamuri A, Stoye JP, Tedder RS (2011) PCR master mixes harbour murine DNA sequences. Caveat emptor! PloS one 6: e19953.
- 32. Erlwein O, Robinson MJ, Kaye S, Wills G, Izui S, et al. (2011) Investigation into the presence of and serological response to XMRV in CFS patients. PloS one 6: e17592.
- 33. Frankel WN, Stoye JP, Taylor BA, Coffin JM (1990) A linkage map of endogenous murine leukemia proviruses. Genetics 124: 221–236.